Evidence map›Paper›PMID 35086475›Full record

ArticleBMC infectious diseases2022

Genetic diversity in L1 ORF of human papillomavirus in women with cervical cancer with and without human immunodeficiency virus in Botswana and Kenya.

Leabaneng Tawe, Wonderful T Choga, Giacomo M Paganotti, Ontlametse T Bareng, Tlhalefo D Ntereke, Pleasure Ramatlho, Doreen Ditshwanelo, Simani Gaseitsiwe, Ishmael Kasvosve, Doreen Ramogola-Masire and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Leabaneng TaweDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Private Bag 00712, Gaborone, Botswana. tleabaneng@yahoo.com.
Wonderful T ChogaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Giacomo M PaganottiBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Ontlametse T BarengDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Private Bag 00712, Gaborone, Botswana.
Tlhalefo D NterekeBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Pleasure RamatlhoDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Private Bag 00712, Gaborone, Botswana.
Doreen DitshwaneloBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Ishmael KasvosveDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Private Bag 00712, Gaborone, Botswana.
Doreen Ramogola-MasireDepartment of Obstetrics and Gynaecology, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Omenge E Orang'oMoi University, Eldoret, Kenya.
Erle RobertsonDepartment of Otorhinolaryngology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nicola ZetolaBotswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Surbhi Grover *Botswana-University of Pennsylvania Partnership, Gaborone, Botswana.
Aaron C Ermel *Indiana University School of Medicine, Indianapolis, IN, USA.
University of Botswana · BWBotswana Harvard AIDS Institute Partnership · BWIndiana University – Purdue University Indianapolis · USMoi University · KEUniversity of Cape Town · ZAUniversity of Pennsylvania · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Shared Resources CoreU54CA190158 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2014 to 2023
$4.2M
Prognostic value of quantitative HPV viral load in determining cervical cancer treatment response and recurrenceK08CA230170 · NCI · UNIVERSITY OF PENNSYLVANIA · PI GROVER, SURBHI · 2019 to 2023
$1.4M
FIC NIH HHS D43 TW009610NCI NIH HHS K08 CA230170NCI NIH HHS U54 CA190158NIAID NIH HHS P30 AI045008Penn Center for AIDS Research 5-P30-AI- 045008-17Sub-Saharan African Collaborative HIV and Cancer Consortia-U54 1U54 CA190158-01Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) DEL-15-006
6 · The paper itself

Abstract

backgroundThe variation of human papillomavirus (HPV) genotypes shapes the risks of cervical cancer and these variations are not well defined in Africa. Nucleotide changes within the L1 gene, nucleotide variability, and phylogeny were explored in relation to HIV in samples from Botswana and Kenya.

methodsA total of 98 HPV-positive cervical samples were sequenced to identify different HPV variants. Phylogenetic inferences were used to determine HPV genotypes and investigate the clustering of sequences between women living with HIV (WLWHIV) and -women not living with HIV (WNLWHIV).

resultsOut of 98 generated sequences, 83.7% (82/98) participants had high-risk (HR) HPV genotypes while 16.3% (16/98) had low-risk (LR) HPV genotypes. Among participants with HR-HPV genotypes, 47.6% (39/82) were coinfected with HIV. The prevalence of HR-HPV genotypes was statistically higher in the Botswana population compared to Kenya (p-value < 0.001). Multiple amino acid mutations were identified in both countries. Genetic diversity differed considerably among WLWHIV and WNLWHIV. The mean pairwise distances between HPV-16 between HIV and HIV/HPV as well as for HPV-18 were statistically significant. Six (6) new deleterious mutations were identified in the HPV genotypes based on the sequencing of the L1 region, HPV-16 (L441P, S343P), HPV-18 (S424P), HPV-45 (Q366H, Y365F), and HPV-84 (F458L). The majority of the patients with these mutations were co-infected with HIV.

conclusionsGenomic diversity and different genomic variants of HPV sequences were demonstrated. Candidate novel mutations within the L1 gene were identified in both countries which can be further investigated using functional assays.

Indexed as

AlphapapillomavirusHIV InfectionsPapillomavirus InfectionsUterine Cervical NeoplasmsBotswanaFemaleGenetic VariationGenotypeHIVHumansKenyaPapillomaviridaePhylogenyBotswanaCervical cancerHIVHIV co-infectionHPV variants phylogenetic analysisHuman papillomavirusKenyaL1 gene

Identifiers

PMID35086475
PMCPMC8796425
OpenAlexW4210805571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.